FUNDAMENTALS · Fundamentals · US Healthcare

Korro Bio (KRRO) Fundamentals 2026 — Revenue Analysis | SniperIQ

Korro Bio (KRRO) is a US-listed Healthcare company in Biotechnology with a market capitalization of

15M, trading at
1.57 on the NASDAQ. This SniperIQ fundamentals page covers Korro Bio's valuation, profitability (net margin -2954.1%), revenue ($6M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
15M
Net Margin-2954.1%
Revenue (FY25)$6M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Korro Bio's market cap?

Korro Bio (KRRO) has a market capitalization of approximately

15M, trading at
1.57 on the NASDAQ. Market cap moves with the live share price.

What is Korro Bio's P/E ratio?

Korro Bio's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Korro Bio?

Korro Bio runs a net profit margin of -2954.1%, a gross margin of 73.2%, and an operating margin of -2154.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Korro Bio generate?

Korro Bio reported revenue of $6M for fiscal year 2025, with net income of -

17M and earnings per share (EPS) of -12.48. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Korro Bio pay a dividend?

Korro Bio does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Korro Bio financially healthy?

Korro Bio carries a debt-to-equity ratio of 0.36x and a current ratio of 8.13x, with a market beta of 2.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Korro Bio a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Korro Bio (KRRO) the key facts are: market cap

15M, revenue $6M, 52-week range 5.204-55.89. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Korro Bio's full fundamentals live

Get Korro Bio's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Fortress Biotech (FBIO) fundamentals · Polaryx Therapeutics, Inc. Common Stock (PLYX) fundamentals · Unicycive Therapeutics (UNCY) fundamentals · Seer (SEER) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons